Nuohua (NVS) After the pharmacist defeated the fourth quarter expectations, (NVS) stocks rose moderately, which to a large extent on the back of its heart failure drug Entresto.

Entresto is Nuohua's biggest money -making person. In the December quarter, the drug's sales were US $ 2.18 billion. According to FACTSET data, sales increased by 33 % year -on -year, defeating the prediction at a price of $ 2.01 billion.

↑ X Now How to buy stock: IBD's four investment pillars

However, the patent to protect Entresto will expire in July, making heart failure drugs open to general competition. In fact, Novartis has expected the United States to compete for ENTRESTO, Tasigna and Promacta in mid -2025. Tasigna is a cancer drug, and Promacta treats hypertrophic boards.

The latter drugs are the top contributors of Novartis. Their comprehensive sales were $ 994 million in the fourth quarter.

In the morning trading, Novartis's stock price rose 1.7 % to 106.53.

Novartis: benefits, the highest sales prediction

Nohua's core revenue in the fourth quarter was $ 1.98 per share, with sales of $ 13.15 billion. The income jumped by 29 %, predicting the price of $ 1.80 per share. According to FactSet data, sales increased by 15 %, and at a price of $ 12.84 billion.

Novartis said that this also saw the power of KESIMPTA, Kisqali, Cosentyx and Leqvio in December. KESIMPTA treats multiple sclerosis. Kisqali is a cancer drug, and Cosentyx treats immunology conditions. Leqvio is a cholesterol drug.

It is worth noting that among patients with established cardiovascular diseases and LP elevations (A), Novartis has shifted its third -stage study of drug research. LP (A) or lipoprotein A is similar to "bad" LDL cholesterol. LP (A) elevation is considered a risk factor for cardiovascular disease. Novartis is now expected to be packaged in 2026.

Leerink Partners Analyst Mani FOROOHAR said in a report: "It is expected that the incident -driven test will be read in mid -25 years, representing the main catalyst in the heart metabolic space."

Many other companies are targeted at LP (A), including Anjin (AMGN), Yililai (Lly), IONIS PHARMACEUTILS (ion), CRISPR therapy (CRSP) and NewAmsterdam Pharma (NAMS).

You may also like:

The scientific gap between thermo Fisher is getting closer and closer to the purchase point, with a strong income section

Teva stock dive 14 %. CEO said, "We are our own victims."

Find the best long -term investment with IBD long -term leaders

IBD number: today's unlock IBD's senior stock list, tools and analysis

How to study growth inventory: Why does this IBD tool simplify the search for top -level stocks